Clinical trials: Non-segmental Vitiligo
Non-segmental Vitiligo, Vitiligo
ReNovaCell in Non-segmental Vitiligo
Rationale: Autologous epidermal cell suspension grafting is an effective method of surgical treatment in vitiligo, which is suitable for treating large areas with good cosmetic results.
- Trial name
- NCT03022019
- Testing
- ReNovaCell
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Netherlands Institute for Pigment Disorders
Skin and Connective Tissue Diseases, Skin Diseases
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with…
- Conditions
- Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder, Hypopigmentation
- Trial name
- TILDVIT-1227 (NCT04971200)
- Testing
- Tildrakizumab
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Premier Specialists, Australia
Vitiligo
Fractional Laser in Combination With UVB Therapy in Vitiligo Patients
Rationale: Vitiligo is a common skin disorder that can impair a patient's quality of life. Many depigmented lesions in vitiligo patients remain therapy resistant for medical treatment.
- Trial name
- NCT02290717
- Testing
- Fractional CO2 laser, NB-UVB therapy, Fluticasone Propionate Cream 0.05%
- Where
- Netherlands
- Sponsor
- Netherlands Institute for Pigment Disorders
Vitiligo, Secukinumab
Secukinumab in Active Non-segmental Vitiligo
Vitiligo is an acquired autoimmune skin disorder which leads to cutaneous depigmentations. A lot of progress has been made to unravel the pathophysiology of vitiligo.
- Trial name
- NCT05676333
- Testing
- Secukinumab
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- University Hospital, Ghent
Pigmentation Disorders, Vitiligo
Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control
Tacrolimus ointment 0.1% has shown promising results for treating vitiligo in many prospective studies. Prospective randomized studies versus placebo are required to confirm the hypothesis that maintenance treatment with two…
- Trial name
- NCT01841008
- Testing
- Protopic
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Non-segmental Vitiligo
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
- Trial name
- NCT07105254
- Testing
- Roflumilast topical 0.3% foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Texas, PLLC
Active Non Segmental Vitiligo
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
This study aims at evaluating the effect of NB-UVB on tissue level of IL-15 and IL-15 receptor alpha subunit (IL-15Rα)(CD215) in active non segmental vitiligo.
- Trial name
- NCT05316987
- Testing
- Narrow band ultraviolet B
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04052425
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Non-segmental Vitiligo
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.
- Trial name
- NCT04811326
- Testing
- NB-UVB, Latanoprost
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shaimaa Fawzy Abdel-rady Abdel-latif
Non-segmental Vitiligo
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.
- Trial name
- NCT07251595
- Testing
- SHR0302 Tablets, SHR0302 Base Gel
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vitiligo
Assessment of Hypoxia Inducible Factor and Autophagy Related Genes in Patients With Non-Segmental Vitiligo
The present study will aim to evaluate: 1. The presence of Hypoxia Inducible Factor in vitiligo patient 2. Defect of Autophagy Related Genes in vitiligo patient 3.
- Trial name
- NCT06410898
- Testing
- Punch Biopsy 5mm
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sohag University
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Vitiligo
Effect of Procedural Variables on Outcome of Surgical Treatment of Vitiligo
ORSHFS grafts yielded lower cell counts than NCECS but the M-K ratio and resultant repigmentation did not show significant difference with better healing of the donor site.
- Trial name
- NCT02510651
- Testing
- Melanocyte-keratinocyte suspension
- Volunteers
- 40 people
- Sponsor
- Cairo University
Non-segmental Vitiligo, Segmental Vitiligo
Punchgrafting Techniques for Vitiligo
Rationale: Punch grafting is a safe, simple and widely used technique for in vitiligo. However, no reliable data are available on the effect of punch depth and punch size.
- Conditions
- Non-segmental Vitiligo, Segmental Vitiligo, Piebaldism
- Trial name
- MiniSNIP (NCT01377077)
- Testing
- punchgrafting
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Vitiligo Vulgaris
Possible Augmentation Of NB-UVB Induced Pigmentation In NSV By Carboxy.
Patients with stable vitiligo with 2 or more symmetric patches, 2 on acral sites and/or 2 on non acral sites will be recruited and assessed for eligibility for inclusion to receive NB-UVB on the whole body, and carboxytherapy on…
- Trial name
- NB-UVB (NCT07563049)
- Testing
- NB-UVB alone, NB-UVB combined with carboxy
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Kasr El Aini Hospital
Non-segmental Vitiligo
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation.
- Trial name
- NCT07223229
- Testing
- EI-001
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 45 people
- Sponsor
- Elixiron Immunotherapeutics (Hong Kong) Ltd.
Vitiligo, Non-Segmental Vitiligo (NSV)
Study of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
- Trial name
- D2570-206 (NCT07625891)
- Testing
- D-2570 Dose 1, D-2570 Dose 2, D-2570 Dose 3
- Where
- China
- Volunteers
- 160 people
- Sponsor
- InventisBio Co., Ltd